Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories

Journal of Clinical Oncology

Volumn 30, Issue 17, 2012, Pages 2140-2146

  Cornelissen, Jan J ^a   Breems, Dimitri ^g   Van Putten, Wim L J ^a   Gratwohl, Alois A ⁱ   Passweg, Jakob R ⁱ   Pabst, Thomas ^j   Maertens, Johan ^h   Berna Beverloo, H ^a   Van Marwijk Kooy, Marinus ^b   Wijermans, Pierre W ^c   Biemond, Bart J ^d   Vellenga, Edo ^f   Verdonck, Leo F ^b   Ossenkoppele, Gert J ^e   Loẅenberg, Bob ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

^c HAGA HOSPITAL   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g Hospital Campus Stuivenberg ^*  (Netherlands)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CHROMOSOME ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CYTOGENETICS; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84863952219     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.6499     Document Type: Article

References (29)

1. Grimwade D, Hills RK, Moorman AV, et al: Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-365, 2010
2. Grimwade D, Hills RK: Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 385-395, 2009
3. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96:4075-4083, 2000
4. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia group B (CALBG 8461). Blood 100:4325-4336, 2002 (Pubitemid 35429670)
5. Mrózek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18:115-136, 2004 (Pubitemid 38380667)
6. Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
7. Breems DA, Van Putten WL, De Greef GE, et al: Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26:4791-4797, 2008
8. Breems DA, Löwenberg B: Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. Haematologica 96:491-493, 2011
9. Medeiros BC, Othus M, Fang M, et al: Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: The Southwest Oncology Group (SWOG) experience. Blood 116:2224-2228, 2010
10. Patnaik MM, Hanson CA, Hodnefield JM, et al: Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia 25:266-270, 2012
11. Perrot A, Luquet I, Pigneux A, et al: Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: A GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood 118:679-685, 2011
12. Cornelissen JJ, van Putten WL, Verdonck LF, et al: Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood 109:3658-3666, 2007 (Pubitemid 46641712)
13. Koreth J, Schlenk R, Kopecky KJ, et al: Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349-2361, 2009
14. Oran B, Dolan M, Cao Q, et al: Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 17:356-364, 2011
15. Stelljes M, Beelen DW, Braess J, et al: Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: Landmark analysis from a single prospective multicenter trial. Haematologica 96:972-979, 2011
16. Fang M, Storer B, Estey E, et al: Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood 118:1490-1494, 2011
17. Löwenberg B, Boogaerts MA, Daenen SM, et al: Value of different modalities of granulocytemacrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 15:3496-3506, 1997 (Pubitemid 27527723)
18. Löwenberg B, van Putten W, Theobald M, et al: Effect of priming with granulocyte colonystimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 349:743-752, 2003 (Pubitemid 37010778)
19. Breems DA, Boogaerts MA, Dekker AW, et al: Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: A prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol 128:59-65, 2005
20. Löwenberg B, Ossenkoppele GJ, van Putten W, et al: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361:1235-1248, 2009.
21. Shaffer LG, Slovak ML, Campbell LJ (eds): ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009). Basel, Switzerland, Karger, 2009
22. Mantel N, Byar DP: Evaluation of responsetime data involving transient states: An illustration using heart-transplant data. J Am Stat Assoc 69:81-86, 1974
23. Schlenk RF, Döhner K, Mack S, et al: Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 28:4642-4648, 2010
24. Hermans J, Suciu S, Stijnen T, et al: Treatment of acute myelogenous leukemia: An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. Eur J Cancer Clin Oncol 25:545-550, 1989 (Pubitemid 19061776)
25. Burnett AK, Hills RK, Milligan DW, et al: Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol 28:586-595, 2010
26. Schrauder A, Reiter A, Gadner H, et al: Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: Results from ALL-BFM 90 and 95. J Clin Oncol 24:5742-5749, 2006 (Pubitemid 46631317)
27. Schetelig J, Bornhäuser M, Schmid C, et al: Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: A report from the cooperative German Transplant Study group. J Clin Oncol 26:5183-5191, 2008
28. Schmid C, Schleuning M, Schwerdtfeger R, et al: Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108:1092-1099, 2006 (Pubitemid 44154650)
29. de Lima M, Giralt S, Thall PF, et al: Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome. A dose and schedule finding study. Cancer 116:5420-5431, 2010